Literature DB >> 29566427

Risk of major amputation in patients with intermittent claudication undergoing early revascularization.

J Golledge1,2,3,4, J V Moxon1,2, S Rowbotham1,5,6, J Pinchbeck1, L Yip1, R Velu3,4, F Quigley4, J Jenkins6, D R Morris1,7.   

Abstract

BACKGROUND: Revascularization is being used increasingly for the treatment of intermittent claudication and yet few studies have reported the long-term outcomes of this strategy. The aim of this study was to compare the long-term outcome of patients with intermittent claudication who underwent revascularization compared with a group initially treated without revascularization.
METHODS: Patients with symptoms of intermittent claudication and a diagnosis of peripheral arterial disease were recruited from outpatient clinics at three hospitals in Queensland, Australia. Based on variation in the practices of different vascular specialists, patients were either treated by early revascularization or received initial conservative treatment. Patients were followed in outpatient clinics using linked hospital admission record data. The primary outcome was the requirement for major amputation. Kaplan-Meier curves, Cox regression and competing risks analyses were used to compare major amputation rates.
RESULTS: Some 456 patients were recruited; 178 (39·0 per cent) underwent early revascularization and 278 (61·0 per cent) had initial conservative treatment. Patients were followed for a mean(s.d.) of 5·00(3·37) years. The estimated 5-year major amputation rate was 6·2 and 0·7 per cent in patients undergoing early revascularization and initial conservative treatment respectively (P = 0·003). Early revascularization was associated with an increased requirement for major amputation in models adjusted for other risk factors (relative risk 5·40 to 4·22 in different models).
CONCLUSION: Patients presenting with intermittent claudication who underwent early revascularization appeared to be at higher risk of amputation than those who had initial conservative treatment.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29566427     DOI: 10.1002/bjs.10765

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.

Authors:  Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

Review 2.  Update on the pathophysiology and medical treatment of peripheral artery disease.

Authors:  Jonathan Golledge
Journal:  Nat Rev Cardiol       Date:  2022-01-07       Impact factor: 32.419

3.  Race and socioeconomic differences associated with endovascular peripheral vascular interventions for newly diagnosed claudication.

Authors:  Caitlin W Hicks; Peiqi Wang; William E Bruhn; Christopher J Abularrage; Ying W Lum; Bruce A Perler; James H Black; Martin A Makary
Journal:  J Vasc Surg       Date:  2020-01-02       Impact factor: 4.268

4.  High ankle brachial index predicts high risk of cardiovascular events amongst people with peripheral artery disease.

Authors:  Jonathan Golledge; Joseph V Moxon; Sophie Rowbotham; Jenna Pinchbeck; Frank Quigley; Jason Jenkins
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

5.  Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease.

Authors:  Kristen J Bubb; Jason A Harmer; Meghan Finemore; Sarah Joy Aitken; Zara S Ali; Laurent Billot; Clara Chow; Jonathan Golledge; Rebecca Mister; Michael P Gray; Stuart M Grieve; Naomi Hamburg; Anthony C Keech; Sanjay Patel; Vikram Puttaswamy; Gemma A Figtree
Journal:  BMJ Open       Date:  2021-09-28       Impact factor: 2.692

6.  Outcomes of endovascular treatment of patients with intermittent claudication due to femoropopliteal disease.

Authors:  Ahmed A Naiem; Robert James Doonan; Oren K Steinmetz; Kent S MacKenzie; Elie Girsowicz; Jason P Bayne; Daniel I Obrand; Heather L Gill
Journal:  Vascular       Date:  2021-08-16       Impact factor: 1.105

7.  Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization.

Authors:  Kshitij Desai; Britta Han; Laila Kuziez; Yan Yan; Mohamed A Zayed
Journal:  J Vasc Surg       Date:  2020-09-04       Impact factor: 4.268

8.  Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease.

Authors:  Jonathan Golledge; Sophie Rowbotham; Ramesh Velu; Frank Quigley; Jason Jenkins; Michael Bourke; Bernie Bourke; Shivshankar Thanigaimani; Dick C Chan; Gerald F Watts
Journal:  J Am Heart Assoc       Date:  2020-03-14       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.